Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes

Anemia is a frequent cytopenia in myelodysplastic syndromes (MDS) and most patients require red blood cell transfusion resulting in iron overload (IO). Deferasirox (DFX) has become the standard treatment of IO in MDS and it displays positive effects on erythropoiesis. In low risk MDS samples, mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Meunier, Mathieu, Ancelet, Sarah, Lefebvre, Christine, Arnaud, Josiane, Garrel, Catherine, Pezet, Mylène, Wang, Yan, Faure, Patrice, Szymanski, Gautier, Duployez, Nicolas, Preudhomme, Claude, Biard, Denis, Polack, Benoit, Cahn, Jean-Yves, Moulis, Jean Marc, Park, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739655/
https://www.ncbi.nlm.nih.gov/pubmed/29285268
http://dx.doi.org/10.18632/oncotarget.22299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739655/
https://www.ncbi.nlm.nih.gov/pubmed/29285268
http://dx.doi.org/10.18632/oncotarget.22299

Ejemplares similares